BIOCRYST PHARMACEUTICALS, INC. (BCRX) FY2026 Q2 Statement of Cash Flows
2026-04-01 to 2026-06-30
Statement of Cash Flows
2026-04-01 to 2026-06-30
Swipe to see the full flow
Chart details
BIOCRYST PHARMACEUTICALS, INC. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026
Cash flows for Apr 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Mar 31, 2026. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.
- Beginning cash on Mar 31, 2026
- 173,378,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
- Operating activities
- 104,342,000 US dollars. Net cash provided.
- Net (loss) income
- 78,395,000 US dollars
- Depreciation
- 513,000 US dollars
- Acquired in-process research and development
- 0 US dollars
- Amortization of assembled workforce
- 0 US dollars
- Inventory obsolescence
- 509,000 US dollars
- Stock-based compensation expense
- 14,692,000 US dollars
- Mark-to-market adjustment on share-based liability
- 524,000 US dollars
- Payment of Pharmakon paid-in-kind interest
- 0 US dollars
- Non-cash interest expense on royalty financing obligations
- 13,036,000 US dollars
- Amortization of debt issuance costs on term loans
- 203,000 US dollars
- Amortization of discount on investments, net
- negative 417,000 US dollars
- Loss on extinguishment of debt
- 0 US dollars
- Increase in trade receivables
- negative 1,485,000 US dollars
- (Increase) decrease in inventory
- negative 4,349,000 US dollars
- Decrease in prepaid expenses and other assets
- 4,432,000 US dollars
- Decrease in royalty financing obligations
- negative 18,318,000 US dollars
- Decrease in accounts payable and accrued expenses
- 5,065,000 US dollars
- Increase in deferred revenue
- 11,542,000 US dollars
- Investing activities
- negative 110,148,000 US dollars. Net cash used.
- Acquisitions of property and equipment
- negative 209,000 US dollars
- Purchases of investments
- negative 135,635,000 US dollars
- Sales and maturities of investments
- 25,696,000 US dollars
- Acquisition of Astria Therapeutics, Inc., net of cash acquired
- 0 US dollars
- Financing activities
- negative 11,153,000 US dollars. Net cash used.
- Net proceeds from common stock issued under stock-based compensation plans
- 6,203,000 US dollars
- Withholding taxes paid on stock-based awards
- negative 3,692,000 US dollars
- Common stock issued to directors in lieu of cash retainer
- 44,000 US dollars
- Proceeds from term loan
- 0 US dollars
- Repayment of Pharmakon term loan principal
- 0 US dollars
- Prepayment premium and fees on Pharmakon term loan
- 0 US dollars
- Payment of debt issuance costs on term loan
- 0 US dollars
- Principal payments on royalty financing obligations
- negative 13,347,000 US dollars
- Principal payments on finance lease liabilities
- negative 361,000 US dollars
- Operating adjustment reconciliation
- 50,516,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
- financing gross reconciliation
- 17,400,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- investing gross reconciliation
- 135,844,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- Exchange-rate effect
- 72,000 US dollars
- Other changes in cash (calculated)
- negative 107,000 US dollars. Out of cash; drawn as the small gray flow above ending cash.
- Ending cash on Jun 30, 2026
- 156,384,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
- Cash sources and uses
- 277,792,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
- Net cash change
- negative 16,994,000 US dollars. Ending cash minus beginning cash.
- Cash flow / Net income
- 1.33×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
- Operating cash flow
- 104,342,000 US dollars. Operating cash flow used in the free cash flow calculation.
- cash spent on productive assets
- 209,000 US dollars. These cash purchases are already included in investing activities above.
- Free cash flow
- 104,133,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.
Chart connections
- Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
- Financing contributions meet at a reconciliation junction before connecting to the net cash total.
- Investing contributions meet at a reconciliation junction before connecting to the net cash total.
- Operating reconciliation adjustments are not all independent cash receipts.
- Net income enters operating cash directly in the reconciliation. The adjustment junction contributes the remaining $25.95M after reconciling the other positive and negative adjustments. These connections depict an accounting reconciliation, not traced cash receipts.
- Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
- The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
- Operating cash flow minus cash spent on productive assets equals free cash flow: 104,342,000 US dollars minus 209,000 US dollars equals 104,133,000 US dollars.
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG
Product waitlist
Health Check and Teardown for your own company
A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!